Literature DB >> 20033322

TGM2 is a novel marker for prognosis and therapeutic target in colorectal cancer.

Norikatsu Miyoshi1, Hideshi Ishii, Koshi Mimori, Fumiaki Tanaka, Toshiki Hitora, Mitsuyoshi Tei, Mitsugu Sekimoto, Yuichiro Doki, Masaki Mori.   

Abstract

BACKGROUND: Transglutaminase 2 (TGM2) plays a role in cell growth and survival through the antiapoptosis signaling pathway.
METHODS: We analyzed TGM2 gene expression in 91 paired cases of colorectal cancer (CRC) and noncancerous regions and seven CRC cell lines to demonstrate the importance of TGM2 expression for the prediction of prognosis of CRC. TGM2 expression was higher in CRC tissue than in corresponding normal tissue by real-time reverse transcriptase-polymerase chain reaction (P = .015).
RESULTS: Patients in the high TGM2 expression group showed a poorer overall survival rate than those in the low expression group (P = .001), indicating that the increase in TGM2 expression was an independent prognostic factor. TGM2 was also expressed in the seven CRC cell lines. The in vitro proliferation assay showed that TGM2 expression is involved with tumor growth.
CONCLUSIONS: The present study suggests that TGM2 is useful as a predictive marker for patient prognosis and may be a novel therapeutic target for CRC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20033322     DOI: 10.1245/s10434-009-0865-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  42 in total

1.  Expression signatures of early-stage and advanced medaka melanomas.

Authors:  Barbara Klotz; Susanne Kneitz; Martina Regensburger; Lena Hahn; Michael Dannemann; Janet Kelso; Birgit Nickel; Yuan Lu; William Boswell; John Postlethwait; Wesley Warren; Manfred Kunz; Ronald B Walter; Manfred Schartl
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2017-11-21       Impact factor: 3.228

2.  Tissue transglutaminase-1 promotes stemness and chemoresistance in gastric cancer cells by regulating Wnt/β-catenin signaling.

Authors:  Haitao Huang; Zhiqi Chen; Xiuqin Ni
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-04

3.  Overexpression of ANXA1 confers independent negative prognostic impact in rectal cancers receiving concurrent chemoradiotherapy.

Authors:  Ming-Jen Sheu; Chien-Feng Li; Ching-Yih Lin; Sung-Wei Lee; Li-Ching Lin; Tzu-Ju Chen; Li-Jung Ma
Journal:  Tumour Biol       Date:  2014-05-09

4.  SLUG silencing increases radiosensitivity of melanoma cells in vitro.

Authors:  Chiara Arienti; Anna Tesei; Silvia Carloni; Paola Ulivi; Antonino Romeo; Giulia Ghigi; Enrico Menghi; Anna Sarnelli; Elisabetta Parisi; Rosella Silvestrini; Wainer Zoli
Journal:  Cell Oncol (Dordr)       Date:  2012-12-19       Impact factor: 6.730

5.  Effect of bexarotene on differentiation of glioblastoma multiforme compared with ATRA.

Authors:  Jin-Chul Heo; Tae-Hoon Jung; Sungjin Lee; Hyun Young Kim; Gildon Choi; Myungeun Jung; Daeyoung Jung; Heung Kyoung Lee; Jung-Ok Lee; Ji-Hwan Park; Daehee Hwang; Ho Jun Seol; Heeyeong Cho
Journal:  Clin Exp Metastasis       Date:  2016-03-08       Impact factor: 5.150

6.  Prognostic role of tissue transglutaminase 2 in colon carcinoma.

Authors:  María Jesús Fernández-Aceñero; Sofía Torres; Irene Garcia-Palmero; Cristina Díaz Del Arco; J Ignacio Casal
Journal:  Virchows Arch       Date:  2016-09-13       Impact factor: 4.064

7.  Mapping of genetic abnormalities of primary tumours from metastatic CRC by high-resolution SNP arrays.

Authors:  José María Sayagués; Celia Fontanillo; María del Mar Abad; María González-González; María Eugenia Sarasquete; Maria del Carmen Chillon; Eva Garcia; Oscar Bengoechea; Emilio Fonseca; Marcos Gonzalez-Diaz; Javier De las Rivas; Luís Muñoz-Bellvis; Alberto Orfao
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

Review 8.  Transglutaminase is a tumor cell and cancer stem cell survival factor.

Authors:  Richard L Eckert; Matthew L Fisher; Dan Grun; Gautam Adhikary; Wen Xu; Candace Kerr
Journal:  Mol Carcinog       Date:  2015-08-10       Impact factor: 4.784

9.  A mechanism for the upregulation of EGF receptor levels in glioblastomas.

Authors:  Jingwen Zhang; Marc A Antonyak; Garima Singh; Richard A Cerione
Journal:  Cell Rep       Date:  2013-06-13       Impact factor: 9.423

10.  Transglutaminase 2 induces intrinsic EGFR-TKI resistance in NSCLC harboring EGFR sensitive mutations.

Authors:  Junyoung Choi; Shinkyo Yoon; Deokhoon Kim; Yong Wha Moon; Chang Hoon Lee; Seyoung Seo; Jaekyung Cheon; Yong Song Gho; Changhoon Kim; Eung Ryoung Lee; Soo-Youl Kim; Kyoungmin Lee; Joo Young Ha; Sook Ryun Park; Sang-We Kim; Kang-Seo Park; Dae Ho Lee
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.